Kristin Benton, MSW | |
622 Riverside Dr, Monroe, LA 71201-6211 | |
(318) 398-0945 | |
Not Available |
Full Name | Kristin Benton |
---|---|
Gender | Female |
Speciality | Case Manager/care Coordinator |
Location | 622 Riverside Dr, Monroe, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1740929397 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | (* (Not Available)) | Secondary |
171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kristin Benton, MSW 622 Riverside Dr, Monroe, LA 71201-6211 Ph: () - | Kristin Benton, MSW 622 Riverside Dr, Monroe, LA 71201-6211 Ph: (318) 398-0945 |
News Archive
Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of protection varies.
Los Angeles Times: Three pharmaceutical firms — Roxane, Abbott Laboratories and B. Braun Medical — "agreed to pay more than $421 million to settle claims of defrauding Medicare and Medicaid — the latest in a string of large healthcare fraud settlements announced by the Justice Department. The drug companies charged one set of prices to doctors and pharmacies but reported another set of inflated figures that were used as benchmarks by government insurers reimbursing healthcare providers, authorities said" (Zajac, 12/8).
The use of cognitive-behavioural therapy to treat tics in Tourette syndrome may be as effective as and even superior to medication in certain cases.
Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has entered into a Cooperative Research and Development Agreement with the Naval Medical Research Center. NMRC will collaborate with Genocea to identify antigens that will be used in the development of a vaccine candidate against Plasmodium falciparum for the prevention of malaria.
› Verified 7 days ago